drugset / Trial / NCT00191048

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

NCT00191048

Phase 4 Completed 105 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.

Timeline

Start
2003-10
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified